

## Q3FY19 Result Update Heritage Foods Ltd.

### Value added drives growth; Reiterate Buy

Heritage posted strong 21% growth in its earnings driven by margin improvement across all its segments. Milk volume for the quarter grew by 6%; while the value added segment posted a 24% growth. Share of value added products is increasing in the portfolio and for the quarter stood at 25% vs 22% in Q3FY18. We continue to like Heritage's increasing pan India presence, aggression towards improving the share of value added product and thereby metamorphosing from a plain vanilla regional play to a value added branded PAN India player. We continue with our Buy rating on the stock with a revised price target of INR650.

### Low milk prices and value add growth drives margins

Heritage's consolidated revenue grew by 7% yoy; driven by milk volume growth of 6% 24% yoy growth in the value added segment. Soft Procurement prices, coupled with improving product mix, resulted in strong gross margin expansion of 116 bps on a yoy basis. The core Operating profit grew 20% yoy at INR 45 crore; while the margin expanded by 110 bps yoy largely led by gross margin expansion. Led by strong operating performance, the net earnings grew 21.3% yoy at INR 20.2 crore.

### FY20- Volumes to be back in double digits; with some impact on margins

The management in its commentary stated that the low milk pricing scenario has been arrested and it is seeing some upward movement in the milk procurement price ahead, which is likely to result in double digit growth for the company. While the realization or the selling prices would witness an increase with a time lag owing to increased competition along with the sentiments towards general election, which can have some marginal impact on the short term margins ahead.

### **Key changes in our FY20 estimates**

Taking cues from the management comments in terms of pressure on margins for FY20; we have downgraded our overall margin estimates by 40 bps from the earlier estimate of 8% to current level of 7.6%, resulting in around 9% downgrade in our FY20 earnings from the earlier estimate of INR 120 crore to INR 107 crore.

### Profitable growth + solid balance sheet + Attractive valuation -re-iterate Buy

Heritage focused strategy of balancing aggression in growth with profitability and efficiency continues to keep us positive on the company. We expect its revenue to grow at a CAGR of 11% while earnings to grow at a CAGR of 40% over FY18-20. We maintain Buy with a revised price target of INR 650 (valued at 25x FY20 + 40% discount of investment value of FRL)

	Q3FY19	Q3FY18	% YoY	Q2FY19	% QoQ	FY18	FY19E	FY20E
Net Sales	619	579	7	619	-0	2,373	2,504	2,908
Growth						-10	6	16
EBITDA	45	38	20	49	-7	130	181	221
Adj. PAT	20	17	21	23	-12	55	84	107
% growth						-18	54	27
EPS	4.4	3.6	-	4.9	-	11.8	18.2	23.1
P/E (x)						41	27	21
EV/EBITDA (x)						19	13	11
RoCE (ex Investment)						21	27	28

#### Sangeeta Tripathi

Research Analyst

Sangeeta.tripathi@edelweissfin.com

**CMP INR: 490** 

Rating: Maintain BUY
Target Price INR: 650

Upside: 33%

Bloomberg:	HTFL:IN
52-week range (INR):	790 /421
Share in issue (cr):	6.34
M cap (INR cr):	2,283
Avg. Daily Vol. BSE/NSE :('000):	100
Promoter Holding (%)	39.90

Date: 04th February, 2019

### Q3FY19 Result Highlights

### **Key management commentary**

**Q3FY19** result takeway- Heritage's topline growth of 7% was aided by milk volume growth of 5% and a robust 24% growth in the value added portfolio. The soft milk pricing scenario, along with aggression from the unorganized and certain state led cooperatives resulted in weak offtake in the state of Maharashtra and Tamil Nadu, while other states like Andhra Pradesh, Telanaga, and Karnataka grew posted double digit volume growth. For 9MFY19 revenue grew by mere 4.1%, on the back of weak pricing.

Gross margin expanded driven by improved spread and better product mix - The gross margin improved 116 bps from 20.1% in Q3FY18 to 21.3% in Q3FY19, led by improvement in spread in liquid milk (low milk procurement prices and stable realization) and faster growth in the high margin value added product portfolio (The value added portfolio grew at 24% yoy. The gross margin expansion would have been higher but

**Revenue to inch towards double digit growth** On the growth front, the company remained positive and expects normal double digit gowth in FY20, driven by its deepening strategy in the existing states of Tamil Nadu, Andhra Pradesh, Telangana, Karnataka and Maharashtra along with wider focus on the newly acquired northern state.

Short term pressure on margins likely on lag milk prices; though long term trend towards margin expansion continues - The management in its commentary stated that the low milk pricing scenario has been arrested and it is seeing some upward movement in the milk procurement price, but the milk realization would not witness a similar increase in the next season or so aided by competitive dynamics along with the general election, thus there can be some impact on the margins for the next 2 quarters.

Marked reduction in fat inventory resulted in higher losses- For 9MFY19, the company posted an inventory loss of INR 33.67 crore Vs INR 14.2 crore in 9MFY18. It has led to reduction in strain on the inventory levels for the company even on comprising some margin element. We believe this speaks of prudence and inventory management efforts of the company on the cost of short term margin gain

Incurred INR 66 crore capex for 9MFY19; and re-iterated guidance of INR 100 crore annual capex for next 3 years time frame

**Southern market still constitutes 80% of the overall sales**- For Q3FY19, AP/Telanga / Kanataka and Tamil Nadu together constituted around 80% of the revenue; while North states contributed around 8-10% revenue, and balance 10% comes from Maharastra.

**Re-iteration of growth led by volumes and value added share** – The management's vision towards doubling of milk procurement from current level of 14 lakh litres to 28-30 lac litres remains intact and its strategy for growth via increasing share of value added products from current 25% level to 40% in next 3-4 years.

## Q3FY19 Result Highlights

Year to March	Q3FY19	Q3FY18	% Change	Q2FY19	% Change	9MFY19	9MFY18	% change
Income from operations	619	579	7	619	-0	1,886	1,812	4.1
Direct costs	487	462	5	483	1	1,477	1,475	0
Gross Profit	132	117	13.0	136	-3	403	337	20
Gross profit margin (%)	21.3	20.1	116	22.0	-66.8	21.4	18.6	278
Employee costs	37	31	18	37	-2	109	94	16
Other expenses	50	48	5	50	0	154	150	3
Total operating expenses	574	541	6	571	1	1,740	1,719	1
EBITDA	45.0	37.6	20	49	-7	145	93	56
EBITDA margin (%)	7.3	6.5	77	7.8	-57	7.7	5.1	257
Depreciation and amortisation	11	10	19	11	2	33	28	21
EBIT	34	28	20	37	-10	112	66	71
Interest expenses	5	5	4	5	9	15	13	19
Profit before tax	30	23	30	35	-12	101	56	79
Provision for tax	10	8	35	13	-23	34	15	122
Profit after tax	20.2	16.7	21.3	23	-12	67	36	85
No. Of Shares (Cr)	4.6	4.6		4.6		4.6	4.6	-
Diluted EPS (INR)	4.4	3.6		4.9		14.4	7.8	85
As a % of Revenue	Q3FY19	Q3FY18	% Change	Q2FY19	% Change	9MFY19	9MFY18	% change
Raw Material Cost	78.7	79.9	-1.2	78.0	0.7	78.3	81.4	-3.1
EBITDA	7.3	6.5	0.8	7.8	-0.6	7.7	5.1	2.6
EBIT	5.4	4.8	0.6	6.0	-0.6	5.9	3.6	2.3
Net Profit	3.3	2.9	0.4	3.7	-0.4	3.5	2.0	1.6
Key Indicators	Q3FY19	Q3FY18	% Change	Q2FY19	% Change			
Value added products	134.7	108.5	24.2%	186.1	(27.63)			
Milk Procurement (lac litres)	14.5	13.7	5.8%	13.5	7.73			
Milk Sales volume (lac litres)	11.1	10.5	5.3%	10.8	3.16			
Milk Selling price	38.9	38.9	-0.1%	38.9	(0.15)			
<b>.</b>					, ,			

32.5 33.9 -4.2% 32.4 0.15

Cost per litre

## **Financials**

Income statement (Consolidated) (INR cr					
Year to March	FY16	FY17	FY18	FY19E	FY20E
Income from operations	2,381	2,643	2,373	2,504	2,908
EBITDA	131	141	130	181	221
Depreciation and amortisation	35	38	38	38	43
EBIT	96	104	93	142	177
Interest expenses	17	11	18	24	25
Other income	7	6	8	8	8
Profit before tax	86	98	82	126	160
Provision for tax	31	31	27	42	53
Core profit	55	67	55	84	107
Extraordinary items	1	0	0	0	0
Profit after tax	56	67	55	84	107
Minority Interest	0	0	0	0	0
Share from associates	0	0	0	0	0
Adjusted net profit	56	67	55	84	107
Equity shares outstanding (mn)	5	5	5	5	5
EPS (INR) basic	11.9	14.4	11.8	18.2	23.1
Diluted shares (Cr)	4.6	4.6	4.6	4.6	4.6
EPS (INR) fully diluted	11.9	14.4	11.8	18.2	23.1
Dividend per share	0.0	0.0	0.0	0.0	0.0
Dividend payout (%)	0.0	0.0	0.0	0.0	0.0

# Common size metrics- as % of net revenues

Year to March	FY16	FY17	FY18	FY19E	FY20E
Operating expenses	94.5	94.7	94.5	92.8	92.4
Depreciation	1.4	1.4	1.6	1.5	1.5
Interest expenditure	0.7	0.4	0.8	1.0	0.9
EBITDA margins	5.5	5.3	5.5	7.2	7.6
Net profit margins	2.4	2.5	2.3	3.4	3.7

### **Growth metrics (%)**

Year to March	FY16	FY17	FY18	FY19E	FY20E
Revenues	14.8	11.0	(10.2)	5.5	16.1
EBITDA	56.5	7.9	(7.7)	38.5	22.3
PBT	119.7	14.3	(16.6)	53.7	27.0
Net profit	96.5	20.5	(17.9)	53.9	27.0
EPS	96.5	20.5	(17.9)	53.9	27.0

## **Financials**

Balance sheet ( Consolidated)					(INR cr)
As on 31st March	FY16	FY17	FY18	FY19E	FY20E
Equity share capital	23	23	23	23	23
Preference Share Capital	0	0	0	0	0
Reserves & surplus	217	280	754	839	946
Shareholders funds	240	303	778	862	969
Secured loans	125	69	109	109	109
Unsecured loans	1	66	142	142	142
Borrowings	126	194	251	251	251
Minority interest	0	0	0	0	0
Sources of funds	366	498	1,028	1,113	1,220
Gross block	518	524	715	815	915
Depreciation	206	244	282	320	364
Net block	312	280	433	495	551
Capital work in progress	10	10	9	9	9
Total fixed assets	322	290	442	503	560
Unrealised profit	0	0	0	0	0
Investments	1	149	576	576	576
Inventories	145	123	155	144	167
Sundry debtors	29	16	13	14	16
Cash and equivalents	45	35	99	109	168
Loans and advances	9	16	4	4	4
Other current assets	0	0	0	0	0
Total current assets	228	189	271	272	355
Sundry creditors and others	158	173	220	206	239
Provisions	16	12	13	13	13
Total CL & provisions	174	185	233	219	252
Net current assets	54	4	38	53	103
Net Deferred tax	-19	-19	-19	-19	-19
Misc expenditure	8	0	0	0	0
Uses of funds	366	424	1,037	1,113	1,220
Book value per share (INR)	52	65	168	186	209

Cash flow statement (IN					(INR cr)
Year to March	FY16	FY17	FY18	FY19E	FY20E
Net profit	55	67	55	84	107
Add: Depreciation	35	38	38	38	43
Add: Misc expenses written off	2	8	0	0	0
Add: Deferred tax	-0	0	-0	0	0
Add: Others	0	0	0	0	0
Gross cash flow	91	113	92	123	151
Less: Changes in W. C.	-19	-39	-31	4	-8
Operating cash flow	110	152	123	119	158
Less: Capex	66	21	166	109	100
Free cash flow	44	131	-43	10	58

## **Financials**

### **Ratios**

Year to March	FY16	FY17	FY18	FY19E	FY20E
ROAE (%)	25.6	24.6	10.1	10.3	11.7
ROACE (%)	25.6	24.6	12.2	13.0	15.0
Current ratio	1.3	1.0	1.2	1.2	1.4
Debt/Equity	0.5	0.4	0.3	0.3	0.3
Debtors (days)	4	2	2	2	2
Inventory (days)	22	17	24	21	21
Payable (days)	24	24	34	30	30
Cash conversion cycle (days)	2	-5	-8	-7	-7
Debt/EBITDA	1.0	1.0	1.9	1.4	1.1
Adjusted debt/Equity	0.3	0.3	0.2	0.2	0.1


### **Valuation parameters**

Year to March	FY16	FY17	FY18	FY19E	FY20E
Diluted EPS (INR)	11.9	14.4	11.8	18.2	23.1
Y-o-Y growth (%)	96.5	20.5	(17.9)	53.9	27.0
CEPS (INR)	19.4	22.5	20.0	26.5	32.4
Diluted P/E (x)	41.0	34.0	41.5	26.9	21.2
Price/BV(x)	9.5	7.5	2.9	2.6	2.3
EV/Sales (x)	1.0	0.9	1.0	1.0	0.8
EV/EBITDA (x)	18.0	16.8	18.6	13.4	10.7
Diluted shares O/S	4.6	4.6	4.6	4.6	4.6
Basic EPS	11.9	14.4	11.8	18.2	23.1
Basic PE (x)	41.0	34.0	41.5	26.9	21.2
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0

**Edelweiss Broking Limited**, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kirol Road, Kurla(W) Board: (91-22) 4272 2200

### Vinay Khattar Head Research vinay.khattar@edelweissfin.com

Rating	Expected to
Buy	appreciate more than 15% over a 12-month period
Hold	appreciate between 5-15% over a 12-month period
Reduce	Return below 5% over a 12-month period





### Disclaimer

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups — Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231; Name of the Compliance Officer: Mr. Brijmohan Bohra, Email ID: complianceofficer.ebl@edelweissfin.com Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098; Tel. 18001023335/022-42722200/022-40094279

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No.INH000000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The dis

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of publication or research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No EBL has financial interest in the subject companies: No

EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:



#### Disclaimer

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

#### Additional Disclaimer for U.S. Persons

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

#### Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

#### Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services

#### Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups — Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172.